-11.6%
ONDS vs MRNA
+945.0%
-956.6%
-62.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -9.0% | +13.1% | -22.1% | -9.4% |
| 7D | -23.2% | +20.6% | -43.8% | -23.6% |
| 30D | -29.0% | +27.1% | -56.1% | -29.5% |
| 3M | -40.5% | +353.4% | -393.9% | -45.5% |
| 6M | -45.8% | +446.3% | -492.1% | -53.9% |
| YTD | -46.0% | +776.2% | -822.2% | -61.2% |
| 1Y | -11.6% | +987.9% | -999.5% | -38.4% |
| All | -11.6% | +945.0% | -956.6% | -38.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling